Denca is under control at SAFC plant in Scotland

Published: 6-Jun-2011
Manufacturing Pharmaceutical

Will supply full control system for IPB2 facility at Irvine

Automation control systems specialist Denca Controls has been awarded the E&I controls contract for the new IPB2 facility being designed by laboratory and cleanroom specialist T Squared for SAFC, a leader in biochemical and organic chemical products, based in Irvine, Scotland.

The project involves building and automating a cell culture media, reagents and buffer solutions manufacturing system, CIP system, WFI/SIP system and filling system at the SAFC facility.

Denca, based in Widnes, Cheshire, will supply a full control system consisting of E&I design, manufacture of system control panels, including motor control panel, PLC/instrument control panel and multiple remote I/O, solenoid, HMI panels, system software and associated validation documentation to GAMP (Good Automated Manufacturing Practices), installation and testing/commissioning through to client handover.

See more

You may also like

Manufacturing

Denca designs control system for pharma facility

Read more
Project in Liverpool worth £500,000

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  3. AI-designed drug product enters clinical development Phase I study of an AI-designed oral formulation sets a new standard in drug development
  4. Cutting-edge wiped film evaporator installation – non-tobacco nicotine products Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
  5. Nestlé Health Science and IdB partner to bring VOWST to Europe Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Denca designs control system for pharma facility

Project in Liverpool worth £500,000
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Subscribe now